Predicted protein targets (top 2)
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7573768 | 0.86 | EDNRA (0.61) | EDNRAEDNRB | |
| SCHEMBL8043625 | 0.79 | EDNRB (0.76) | EDNRAEDNRB | |
| SCHEMBL1037267 | 0.78 | EDNRA (0.56) | EDNRAEDNRB | |
| SCHEMBL8443428 | 0.78 | EDNRA (0.57) | EDNRAEDNRB | |
| SCHEMBL6785297 | 0.77 | EDNRA (0.66) | EDNRAEDNRB | |
| SCHEMBL7569655 | 0.77 | EDNRA (0.60) | EDNRAEDNRB | |
| SCHEMBL7567461 | 0.77 | EDNRA (0.60) | EDNRAEDNRB | |
| SCHEMBL7569416 | 0.75 | EDNRA (0.59) | EDNRAEDNRB | |
| SCHEMBL6783690 | 0.74 | EDNRA (0.67) | EDNRAEDNRB | |
| SCHEMBL6789107 | 0.74 | EDNRA (0.61) | EDNRAEDNRB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6133442-A | FOR THE TREATMENT OF DISORDERS WHICH ARE ASSOCIATED WITH ENDOTHELIN ACTIVITIES, ESPECIALLY CIRCULATORY DISORDERS SUCH AS HYPERTENSION, ISCHAEMIA, VASOSPASMS AND ANGINA PECTORIS | HOFFMANN-LA ROCHE INC. (US) | 2000-10-17 | — | — | US | disclosed |
| EP-0799206-A1 | ARYL- AND HETARYL-SULFONAMIDE DERIVATIVES, THEIR PREPARATION AND THEIR USE AS ENDOTHELIN ANTAGONISTS | F. HOFFMANN-LA ROCHE AG (CH) | 1997-10-08 | — | — | EP | disclosed |
| WO-1996019455-A1 | ARYL- AND HETARYL-SULFONAMIDE DERIVATIVES, THEIR PREPARATION AND THEIR USE AS ENDOTHELIN ANTAGONISTS | F. HOFFMANN-LA ROCHE AG (CH) | 1996-06-27 | — | — | WO | disclosed |